Cyclacel gains space for sapacitabine as it tweaks Daiichi Sankyo agreement
This article was originally published in Scrip
Executive Summary
Cyclacel has secured an amendment to its in-licensing agreement with Daiichi Sankyo for sapacitabine in a move that takes the pressure off the US venture to get a first approval for its lead product by this September.